Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

AXOVANT ANNOUNCES DOSING OF FIRST PATIENT IN SECOND

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
georgejjl Member Profile
 
Followed By 80
Posts 11,724
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
georgejjl   Tuesday, 04/30/19 07:50:31 PM
Re: georgejjl post# 745
Post # of 753 
Quote:
AXOVANT ANNOUNCES DOSING OF FIRST PATIENT IN SECOND COHORT OF SUNRISE-PD PHASE 2 TRIAL OF AXO-LENTI-PD
04.30.2019

Download PDF
-Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019-

-Oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy-

BASEL, Switzerland, April 30, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients. To date, the patient has experienced no complications related to the surgery or to administration of the vector and has been discharged home as planned with no serious adverse events observed. Up to 6 patients will be dosed in this second cohort, at a dose of 1.4 x 107 TU, which is approximately 3-fold higher than the dose evaluated in the first cohort. The primary outcome measure in this second cohort is safety and tolerability and a key efficacy measure will be UPDRS Part III (motor) OFF score. Axovant expects initial data from this cohort to be available in the fourth quarter of 2019.

“We are pleased to begin enrolling additional patients in the SUNRISE-PD study at a higher dose level, following encouraging 3-month data from the first cohort,” said Dr. Gavin Corcoran, Axovant’s Chief Research and Development Officer. “We look forward to exploring the full clinical potential of AXO-Lenti-PD in patients with Parkinson’s disease, building upon the safety profile and improvements in motor symptoms that have been observed in 17 patients evaluated across the ProSavin and AXO-Lenti-PD programs. Our focus remains on the rapid execution of the clinical study to evaluate this important potential therapy in patients with Parkinson’s disease.”

These details will be included in Axovant’s oral presentation of previously announced clinical results from the AXO-Lenti-PD study at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place in Washington, DC, April 29 - May 2, 2019.

Title: AXO-LENTI-PD: a second-generation lentiviral gene therapy for the treatment of Parkinson’s Disease (Abstract #222)
Session date/time:April 30, 2019, 3:30-3:45pm ET
Location: Monroe

Additional information on the meeting can be found on the ASGCT website: http://www.asgct.org



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist